Top hospitals are still irate about Genentech's decision to move its best-selling cancer drugs to specialty distributors. And they're not giving up on persuading the company to change back.

The latest salvo comes in the form of a survey by hospital services company Novation, which has been lobbying hard against the Roche ($RHHBY) unit's distribution shift. According to the survey of hospital pharmacy departments, moving Rituxan, Avastin and Herceptin to specialty distribution has increased costs and delayed patient treatment.

The survey was a direct attempt to counter Genentech's case for the change, Novation said. In announcing the new system to customers, Genentech had said that specialty distribution would help prevent shortages, boost efficiency, and keep counterfeits out of the supply chain. Plus, the cancer treatments require special handling and storage, and the company said the new model would help make sure that happens.